Stone S, Henley R, Reynolds T, John R
Medical Biochemistry Department, University Hospital of Wales, Health Park, Cardiff, U.K.
Prenat Diagn. 1993 Jun;13(6):535-7. doi: 10.1002/pd.1970130617.
Free beta-HCG is a new analyte that has been suggested to be superior to total HCG when used in combination with alpha-fetoprotein (AFP) for Down syndrome risk screening in early pregnancy. We have evaluated this claim on 21 samples collected from Down syndrome pregnancies and 180 samples from unaffected pregnancies. The detection rates for the combination of AFP with free beta-HCG or the combination of AFP with total HCG were identical (71 per cent) but the initial screen positive rate (equivalent to the false-positive rate) was 7.5 per cent for AFP + free beta-HCG screening compared with 3.5 per cent for AFP + total HCG screening. We conclude that the case for free beta-HCG is unproven and suggest that further data be collected before free beta-HCG becomes acceptable.
游离β-人绒毛膜促性腺激素是一种新的分析物，有人认为在与甲胎蛋白（AFP）联合用于孕早期唐氏综合征风险筛查时，它优于总人绒毛膜促性腺激素。我们对从唐氏综合征妊娠中采集的21份样本和从正常妊娠中采集的180份样本进行了此项评估。AFP与游离β-人绒毛膜促性腺激素联合检测或AFP与总人绒毛膜促性腺激素联合检测的检出率相同（71%），但AFP + 游离β-人绒毛膜促性腺激素筛查的初始筛查阳性率（相当于假阳性率）为7.5%，而AFP + 总人绒毛膜促性腺激素筛查的为3.5%。我们得出结论，游离β-人绒毛膜促性腺激素的情况尚未得到证实，并建议在游离β-人绒毛膜促性腺激素被接受之前收集更多数据。
